

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2010; month=10; day=20; hr=12; min=58; sec=45; ms=481;
]

=====

Application No: 10591486 Version No: 2.0

Input Set:

Output Set:

Started: 2010-10-15 11:26:09.048
Finished: 2010-10-15 11:26:12.756
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 708 ms
Total Warnings: 4
Total Errors: 12
No. of SeqIDs Defined: 8
Actual SeqID Count: 8

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)

SEQUENCE LISTING

<110> Waugh, Jacob
Dake, Michael

<120> Compositions and Methods for Topical Diagnostic and Therapeutic Transport

<130> 13720-105068US2

<140> 10591486
<141> 2010-10-15

<150> US 11/073,307
<151> 2005-03-03

<150> US 60/550,014
<151> 2004-03-03

<160> 8

<170> PatentIn version 3.4

<210> 1
<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<220>
<221> MOD_RES
<222> (1)..(20)
<223> This region may encompass 0 to 20 Gly residues

<220>
<221> MOD_RES
<222> (1)..(45)
<223> See specification as filed for detailed description of substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (21)..(45)
<223> This region may encompass an odd number of Arg residues from 5 to 25

<400> 1

Gly
1 5 10 15

Gly Gly Gly Arg Arg

20

25

30

Arg
35 40 45

<210> 2
<211> 51
<212> PRT
<213> Human immunodeficiency virus

<220>
<221> misc_feature
<222> (1)..(51)
<223> See specification as filed for detailed description of substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (32)..(51)
<223> This region may encompass 0 to 20 residues

<220>
<221> MOD_RES
<222> (32)..(51)
<223> This region may encompass 0 to 20 residues

<400> 2

Gly
1 5 10 15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly
35 40 45

Gly Gly Gly
50

<210> 3
<211> 51
<212> PRT
<213> Human immunodeficiency virus

<220>
<221> MOD_RES
<222> (1)..(20)
<223> This region may encompass 0 to 20 Gly residues

<220>
<221> misc_feature
<222> (1)..(51)
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (32)..(51)
<223> This region may encompass 0 to 20 Gly residues

<400> 3

Gly
1 5 10 15

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly
35 40 45

Gly Gly Gly
50

<210> 4
<211> 49
<212> PRT
<213> Human immunodeficiency virus

<220>
<221> MOD_RES
<222> (1)..(20)
<223> This region may encompass 0 to 20 Gly residues

<220>
<221> misc_feature
<222> (1)..(49)
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (30)..(49)
<223> This region may encompass 0 to 20 Gly residues

<400> 4

Gly
1 5 10 15

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly
20 25 30

Gly
35 40 45

Gly

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 5

Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10

<210> 6
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<220>
<221> MOD_RES
<222> (1)..(5)
<223> This region may encompass 3 to 5 Gly residues

<220>
<221> MOD_RES
<222> (1)..(22)
<223> See specification as filed for detailed description of
substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (5)..(22)
<223> This region may encompass an odd number of Arg residues from 7
through 17

<400> 6

Gly Gly Gly Gly Arg
1 5 10 15

Arg Arg Arg Arg Arg Arg

20

<210> 7

<211> 12

<212> PRT

<213> Human immunodeficiency virus

<400> 7

Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg

1 5 10

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 8

Arg Arg Arg Arg Arg Arg Arg Arg Arg

1 5